IL-6单核苷酸多态性与老年原发性高血压并发阵发性心房颤动的关系探讨-东南大学学报医学版

IL-6单核苷酸多态性与老年原发性高血压并发阵发性心房颤动的关系探讨

单位：重庆北碚区中医院(广州中医药大学附属重庆医院) 心血管一科, 重庆 400700

分类号：R544.11;R541.75

出版年·卷·期（页码）：2025·44·第三期（440-447）

摘要：

目的: 探究白细胞介素-6(IL-6)单核苷酸多态性与老年原发性高血压并发阵发性心房颤动(PAF)的关系。方法: 选取2020年1月至2023年1月本院收治的279例老年原发性高血压患者作为研究对象,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法检测其IL-6基因-174G/C位点和-572C/G位点单核苷酸多态性,并进行哈迪-温伯格(H-W)遗传平衡性检验。所有患者随访至2024年1月,根据是否并发PAF将其分为PAF组与非PAF组,比较2组患者一般临床资料及IL-6基因单核苷酸多态性;采集2组患者血标本测定血清IL-6水平;单因素及多因素Logistic回归分析法分析老年原发性高血压并发PAF的影响因素。结果: 老年原发性高血压患者随访期间PAF发生率为19.70%(52/264);PAF组患者年龄,有吸烟史占比,高血压分级Ⅲ级占比,IL-6-572C/G位点GG、GC基因型占比和G等位基因频率高于非PAF组(P<0.05);PAF组患者血清IL-6水平高于非PAF组(P<0.05),IL-6-572C/G位点GC、GG基因型患者血清IL-6水平高于IL-6-572C/G位点CC基因型患者(P<0.05);多因素Logistic分析结果显示,年龄[比值比(OR)=1.952,95%置信区间(95%CI):1.281~2.975]、有吸烟史(OR=1.619,95%CI:1.145~2.291)、高血压分级Ⅲ级(OR=1.752,95%CI:1.205~2.548)、IL-6-572C/G位点GC基因型(OR=1.694,95%CI:1.228~2.336)、IL-6-572C/G位点GG基因型(OR=1.846,95%CI:1.176~2.897)是老年原发性高血压并发PAF的独立危险因素(P<0.05)。结论: IL-6-572C/G位点单核苷酸多态性与老年原发性高血压并发PAF有关,年龄、有吸烟史、高血压分级Ⅲ级、IL-6-572C/G位点GC和GG基因型是老年原发性高血压并发PAF的独立危险因素。

Objective: To explore the relationship between interleukin-6(IL-6) single nucleotide polymorphisms and paroxysmal atrial fibrillation(PAF) in elderly patients with primary hypertension. Methods: 279 elderly patients with primary hypertension admitted to our hospital from January 2020 to January 2023 were selected as the study subjects.The polymerase chain reaction restriction fragment length polymorphism(PCR-RFLP) method was used to detect the single nucleotide polymorphisms at the-174G/C and-572C/G sites of the IL-6 gene, and the Hardy Weinberg(H-W) genetic balance test was performed. All patients were followed up until January 2024 and divided into PAF group and non-PAF group according to whether they had concurrent PAF. The general clinical data and IL-6 gene single nucleotide polymorphisms of the two groups were analyzed and compared. Serum IL-6 level was measured by blood samples collected from two groups. The influencing factors of elderly primary hypertension and PAF were analyzed by univariate and multivariate Logistic regression analysis. Results: The incidence of PAF in elderly patients with primary hypertension was 19.70%(52/264). The age of patients, the proportion of smoking history, the proportion of hypertension grade Ⅲ, the proportion of GG, GC genotypes, and the frequencies of G alleles at the IL-6-572C/G site in the PAF group were higher than those in the non PAF group(P<0.05). The serum IL-6 level of patients in the PAF group was higher than that in the non PAF group(P<0.05), and the serum IL-6 level of patients with the IL-6-572C/G site GC genotype and GG genotype were higher than those of patients with the IL-6-572C/G site CC genotype(P<0.05). The results of multivariate Logistic analysis showed that age[odds ratio(OR)=1.952, 95% confidence interval(95% CI): 1.281-2.975], smoking history(OR=1.619, 95% CI: 1.145-2.291), hypertension grade Ⅲ(OR=1.752, 95% CI: 1.205-2.548), IL-6-572C/G site GC genotype(OR=1.694, 95% CI: 1.228-2.336), IL-6-572C/G site GG genotype(OR=1.846, 95% CI: 1.176-2.897) were independent risk factors for elderly primary hypertension with PAF(P<0.05). Conclusion: Single nucleotide polymorphisms at the IL-6-572C/G site is associated with elderly primary hypertension with PAF. Age, smoking history, hypertension grade Ⅲ, and IL-6-572C/G site GC and GG genotype are independent risk factors for elderly primary hypertension with PAF.

参考文献：

[1] GAWAŁKO M, LINZ D.Atrial fibrillation detection and management in hypertension[J].Hypertension, 2023, 80(3):523-533.
[2] GLADSTONE D J, WACHTER R, SCHMALSTIEG-BAHR K, et al.Screening for atrial fibrillation in the older population:a randomized clinical trial[J].JAMA Cardiol, 2021, 6(5):558-567.
[3] RIDKER P M, RANE M.Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J].Circ Res, 2021, 128(11):1728-1746.
[4] PATEL K K, VENKATESAN C, ABDELHALIM H, et al.Genomic approaches to identify and investigate genes associated with atrial fibrillation and heart failure susceptibility[J].Hum Genomics, 2023, 17(1):47.
[5] YUAN S, LIN A, HE Q Q, et al.Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes:a two-sample Mendelian randomization study[J].Int J Cardiol, 2020, 313:99-104.
[6] 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治, 2019, 19(1):1-44.
[7] KOTALCZYK A, LIP G Y, CALKINS H.The 2020 ESC guidelines on the diagnosis and management of atrial fibrillation[J].Arrhythm Electrophysiol Rev, 2021, 10(2):65-67.
[8] MIDDELDORP M E, ARIYARATNAM J P, KAMSANI S H, et al.Hypertension and atrial fibrillation[J].J Hypertens, 2022, 40(12):2337-2352.
[9] 桑明敏, 祝存奎, 马生龙.血清促肾上腺皮质激素与老年高血压合并射血分数保留型心力衰竭患者发生心房颤动的关系[J].实用心脑肺血管病杂志, 2023, 31(8):44-47.
[10] KIM S H, LIM K R, SEO J H, et al.Higher heart rate variability as a predictor of atrial fibrillation in patients with hypertension[J].Sci Rep, 2022, 12(1):3702.
[11] 李静, 甘霖, 蔡孟, 等.单核苷酸多态性对妇科腹腔镜手术后疼痛的影响及基因交互作用研究[J].东南大学学报(医学版), 2024, 43(5):763-770.
[12] SASANO T, IHARA K, TANAKA T, et al.Risk stratification of atrial fibrillation and stroke using single nucleotide polymorphism and circulating biomarkers[J].PLoS One, 2023, 18(10):e0292118.
[13] GOETTE A, LENDECKEL U.Atrial cardiomyopathy:pathophysiology and clinical consequences[J].Cells, 2021, 10(10):2605.
[14] AJOOLABADY A, NATTEL S, LIP G Y H, et al.Inflammasome signaling in atrial fibrillation:JACC state-of-the-art review[J].J Am Coll Cardiol, 2022, 79(23):2349-2366.
[15] LIN K B, FAN F H, CAI M Q, et al.Systemic immune inflammation index and system inflammation response index are potential biomarkers of atrial fibrillation among the patients presenting with ischemic stroke[J].Eur J Med Res, 2022, 27(1):106.
[16] KATKAM S K, RAJASEKHAR L, TASNEEM F S D, et al.Synergetic interaction of HLA-DRB1^*07 allele and TNF-alpha-863 C/a single nucleotide polymorphism in the susceptibility to systemic lupus erythematosus[J].Indian J Clin Biochem, 2021, 36(1):59-66.
[17] SALARI N, MANSOURI K, HOSSEINIAN-FAR A, et al.The effect of polymorphisms(174G>C and 572C>G)on the Interleukin-6 gene in coronary artery disease:a systematic review and meta-analysis[J].Genes Environ, 2021, 43(1):1.
[18] WU F, FENG X, WU Y, et al.Interleukin-6 receptor Asp358 A>C polymorphism is associated with postoperative atrial fibrillation[J].Ann Thorac Surg, 2021, 111(1):102-108.
[19] 付海霞, 张嘉莹, 赵子牛, 等.白细胞介素6基因-597G/A与-572C/G多态性对心房颤动发病易感性的影响[J].中华心律失常学杂志, 2013, 17(3):200-204.
[20] 李娜, 王淑霞, 木胡牙提.IL-6-174G/C及-572C/G位点基因多态性与新疆NVAF人群及民族差异性分析[J].重庆医学, 2017, 46(7):875-878.
[21] LIU Y, WU F, WU Y, et al.Mechanism of IL-6-related spontaneous atrial fibrillation after coronary artery grafting surgery:IL-6 knockout mouse study and human observation[J].Transl Res, 2021, 233:16-31.
[22] SEGAN L, CANOVAS R, NANAYAKKARA S, et al.New-onset atrial fibrillation prediction:the HARMS2-AF risk score[J].Eur Heart J, 2023, 44(36):3443-3452.
[23] LEE S R, CHOI E K, JUNG J H, et al.Smoking cessation after diagnosis of new-onset atrial fibrillation and the risk of stroke and death[J].J Clin Med, 2021, 10(11):2238.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录